Use of antiplatelet therapy and direct oral anticoagulants in candidates for renal transplantation : The French guidelines from the CTAFU
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To define guidelines for the use of antiplatelet therapy (AT) and direct oral anticoagulants (DOAC) in candidates for kidney allotransplantation.
METHOD: A review of the medical literature following a systematic approach was conducted by the CTAFU to report the use of AT and DOAC before major surgery and in the setting of advanced chronic kidney disease, defining their managment prior to kidney transplantation with the corresponding level of evidence.
RESULTS: DOAC are not recommended in patients under dialysis. Aspirin therapy, but not anti-P2Y12 and DOAC, may be maintained during renal transplantation. Anti-P2Y12 and DOAC should not be use in patients awaiting a kidney transplant, except when a living donor is scheduled, therefore authorizing treatment interruption in optimal conditions. Further data regarding DOAC reversion and monitoring may improve their use in this setting. Global level of evidence is weak.
CONCLUSION: These French recommendations should contribute to improve surgical management of kidney transplant candidates exposed to AT or DOA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 31(2021), 1 vom: 11. Jan., Seite 39-44 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : agents antiplaquettaires et anticoagulants oraux directs en transplantation rénale |
|---|
| Beteiligte Personen: |
Timsit, M-O [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.09.2021 Date Revised 02.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.03.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319872610 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319872610 | ||
| 003 | DE-627 | ||
| 005 | 20231225172358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.03.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319872610 | ||
| 035 | |a (NLM)33423745 | ||
| 035 | |a (PII)S1166-7087(20)30682-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Timsit, M-O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of antiplatelet therapy and direct oral anticoagulants in candidates for renal transplantation |b The French guidelines from the CTAFU |
| 246 | 3 | 3 | |a Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : agents antiplaquettaires et anticoagulants oraux directs en transplantation rénale |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2021 | ||
| 500 | |a Date Revised 02.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To define guidelines for the use of antiplatelet therapy (AT) and direct oral anticoagulants (DOAC) in candidates for kidney allotransplantation | ||
| 520 | |a METHOD: A review of the medical literature following a systematic approach was conducted by the CTAFU to report the use of AT and DOAC before major surgery and in the setting of advanced chronic kidney disease, defining their managment prior to kidney transplantation with the corresponding level of evidence | ||
| 520 | |a RESULTS: DOAC are not recommended in patients under dialysis. Aspirin therapy, but not anti-P2Y12 and DOAC, may be maintained during renal transplantation. Anti-P2Y12 and DOAC should not be use in patients awaiting a kidney transplant, except when a living donor is scheduled, therefore authorizing treatment interruption in optimal conditions. Further data regarding DOAC reversion and monitoring may improve their use in this setting. Global level of evidence is weak | ||
| 520 | |a CONCLUSION: These French recommendations should contribute to improve surgical management of kidney transplant candidates exposed to AT or DOA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Agents antiplaquettaires | |
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a Antiplatelet therapy | |
| 650 | 4 | |a Renal Transplantation | |
| 650 | 4 | |a Transplantation rénale | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Branchereau, J |e verfasserin |4 aut | |
| 700 | 1 | |a Matillon, X |e verfasserin |4 aut | |
| 700 | 1 | |a Verhoest, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bessede, T |e verfasserin |4 aut | |
| 700 | 1 | |a LeQuintrec, M |e verfasserin |4 aut | |
| 700 | 1 | |a Boissier, R |e verfasserin |4 aut | |
| 700 | 1 | |a Badet, L |e verfasserin |4 aut | |
| 700 | 1 | |a Smadja, D M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 31(2021), 1 vom: 11. Jan., Seite 39-44 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:1 |g day:11 |g month:01 |g pages:39-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.03.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 1 |b 11 |c 01 |h 39-44 | ||